Physician

Lindsay B. Kelmenson, MD

According to 2025 Medicare claims, Lindsay Kelmenson, MD (NPI: 1457647935) practices rheumatology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Jefferson, AL. This provider's primary affiliated billing organization is RHEUMATOLOGY CARE CENTER, LLC (NPI: 1841425451; TIN: 26-4826862) and primary practice location at 35244-5610.

Kelmenson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 196 traditional Medicare patients, billed 59,263 HCPCS/CPT codes, and received $860,424 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,328 prescription claims across 246 beneficiaries totaling $835,945 in drug costs, led by Xeljanz Xr (Tofacitinib Citrate). Open Payments data shows 179 records totaling $3,539. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,629 to $860,424. Similarly, Part D prescription costs have moved sharply higher in recent years, from $20,218 to $835,945. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$430K$860K2017 Medicare payment: $2,629 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $11,671 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $206,252 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $724,002 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $624,172 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $529,029 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $664,742 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $860,424 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
20172939$2,629
201865278$11,671
20191179,359$206,252
202013534,297$724,002
202116040,559$624,172
202218937,938$529,029
202319557,438$664,742
202419659,263$860,424

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$465K$931K2015 Drug cost: $20,218 (USD; Tot_Drug_Cst)2016 Drug cost: $27,485 (USD; Tot_Drug_Cst)2017 Drug cost: $8,533 (USD; Tot_Drug_Cst)2018 Drug cost: $105,405 (USD; Tot_Drug_Cst)2019 Drug cost: $178,588 (USD; Tot_Drug_Cst)2020 Drug cost: $264,848 (USD; Tot_Drug_Cst)2021 Drug cost: $381,365 (USD; Tot_Drug_Cst)2022 Drug cost: $755,932 (USD; Tot_Drug_Cst)2023 Drug cost: $930,628 (USD; Tot_Drug_Cst)2024 Drug cost: $835,945 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201520158$20,218
20161761$27,485
20172175$8,533
201843184$105,405
201979422$178,588
2020120883$264,848
20211681,474$381,365
20221811,747$755,932
20232061,996$930,628
20242462,328$835,945

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
96413Administration of chemotherapy into vein, 1 hour or less28199$86
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more177340$81
96401Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle58229$49
J0897Injection, denosumab, 1 mg475,040$20
G2211Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's117198$11

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Xeljanz XrTofacitinib Citrate19570$117,738
Taltz AutoinjectorIxekizumab14392$113,680
Enbrel SureclickEtanercept13364$94,619
Orencia ClickjectAbatacept14392$75,142
Hydroxychloroquine SulfateHydroxychloroquine Sulfate60632,643$32,589

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.179$3,539ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Lindsay B. Kelmenson, MD?

Tedicare shows public-source Medicare data for Lindsay B. Kelmenson, MD (NPI 1457647935), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lindsay B. Kelmenson, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Lindsay B. Kelmenson, MD?

Lindsay B. Kelmenson, MD is linked to RHEUMATOLOGY CARE CENTER, LLC (billing NPI 1841425451) in the available physician profile data.

Does Lindsay B. Kelmenson, MD have Open Payments data?

Lindsay B. Kelmenson, MD has 179 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.